HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan. 23, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report that the Independent Data Monitoring Committee for the Company's pivotal trial of NX-1207 for benign prostatic hyperplasia (BPH) has given a positive recommendation based on evaluation of the data in the Company's current pivotal Phase 2 trial. The Independent Data Monitoring Committee is an arm's length independent body which has examined unblinded trial results and reached a favorable conclusion, and has recommended continuation of the trial.
Paul Averback MD, CEO of Nymox, said, "We are excited by the overall near-term prospects of NX-1207, and look forward to the trial's completion. There is considerable and growing interest in Nymox's new BPH drug."
